RCS - SYNLAB International - SYNLAB launches: myEDIT-B

Synlab AGAnnouncement

10/10/2023 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231010:nRSJ6230Pa&default-theme=true

RNS Number : 6627P  SYNLAB International GmbH  10 October 2023

 SYNLAB launches revolutionary bipolar disorder diagnostic test: myEDIT-B

EQS-Media / 10.10.2023 /

 SYNLAB International GmbH

 Moosacher Straße 88

 80809 Munich

 Germany

 Press Release

 Munich, 10 October 2023

 SYNLAB launches revolutionary bipolar disorder diagnostic test: myEDIT-B

 ·      SYNLAB's myEDIT-B is the world's first blood-based test for the
 differential diagnosis between bipolar disorder and unipolar depression

 ·      myEDIT-B allows the diagnosis of bipolar disorder within 24 days,
 improving the prospects for patients significantly by expediting the process
 of identifying the disease

 ·      SYNLAB involved in the whole value chain development of myEDIT-B
 with diagnostics manufacturer Alcediag, within the framework of the EU funding
 programme EITHealth

 ·      SYNLAB's portfolio of specialty tests targeting mental illness
 includes myPSY and myBIOME, which are now complemented by myEDIT-B

 SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty
 testing in Europe, is marking World Mental Health Day 2023 by announcing the
 launch of a revolutionary new test for the diagnosis of bipolar disorder.
 myEDIT-B is the first blood test for the differential diagnosis between
 bipolar disorder and unipolar depression, signalling a paradigm shift in the
 identification of this mental health disorder and thus increasing the
 effectiveness of the treatment approach.

 myEDIT-B is the product of a collaboration between diagnostics manufacturer
 Alcediag and SYNLAB, carried out within the framework of the EU funding
 programme EITHealth. The innovative test is being piloted in Italy and is
 available in other countries through the SYNLAB network.

 myEDIT-B is a CE-IVD certified molecular test that uses RNA-editing
 biomarkers. Following RNA sequencing in the laboratory from a blood sample,
 the myEDIT-B algorithm analyses the RNA editing of profiles of the specific
 genes involved in mechanisms relevant to mood disorders. The test provides
 clinically validated results within 24 days, representing a truly radical leap
 forward in diagnosing the disorder.

 Mental health disorders affect an estimated 84 million people in Europe - 17%
 of the population - with bipolar disorders being diagnosed in 1.3% of the
 European population. The traditional diagnosis of mood disorders is complex
 and subject to a prolonged process. At present, the diagnosis of bipolar
 disorder often extends over several years.

 Research* refers to an average of seven years until a confirmed diagnosis is
 made. In particular, the accurate distinction of bipolar disorder from
 unipolar depression is one of the most important diagnostic needs. While
 initial symptoms are similar, both illnesses require different treatments. A
 major contributor to the long average delay is that an estimated 50% of
 patients are initially misdiagnosed with unipolar depression. As a result,
 patients are at increased risk of hospitalisation, addiction, comorbidity and
 suicide, as well as reduced quality of life.

 The myEDIT-B test complements the existing special diagnostics panel
 supporting the treatment decisions of mental illness. The panel consists of
 myBIOME, an evidence-based functional analysis of the gut microbiome, as well
 as myPSY, an innovative pharmacogenetic test profile for psychotropic drugs
 and antidepressants developed by SYNLAB.

 "On World Mental Health Day 2023, we are proud to reveal this huge development
 in the diagnosis of bipolar disorder and have no doubt that it will have
 profoundly positive impacts on patients of this disease and their loved ones,"
 Mathieu Floreani, CEO of SYNLAB. "myEDIT-B once again demonstrates our passion
 for medical excellence and underscores the value that medical diagnostics and
 specialty testing bring to patients, physicians and healthcare systems."

 *Dagani J, Signorini G, Nielssen O, Bani M, Pastore A, Girolamo G, et al. Meta
 analysis of the Interval between the Onset and Management of Bipolar
 Disorder.Can J Psychiatry. 2017;62:247-58.

For more information:

SYNLAB                           +49 (0) 69 9203 7183

Daniel Herbert, FTI Consulting  Daniel.Herbert@fticonsulting.com (mailto:Daniel.Herbert@fticonsulting.com)

 

 About SYNLAB

 ·      SYNLAB Group is the leader in medical diagnostic services and
 specialty testing in Europe. The Group offers a full range of innovative and
 reliable medical diagnostics to patients, practising doctors, hospitals and
 clinics, governments and corporates.

 ·      Providing the leading level of service within the industry,
 SYNLAB is the partner of choice for routine and specialty diagnostics in human
 and veterinary medicine. The Group continuously innovates medical diagnostic
 services for the benefit of patients and customers.

 ·      SYNLAB operates in more than 30 countries across four continents
 and holds leading positions in most markets, regularly reinforcing the
 strength of its network through a proven acquisition strategy. More than
 28,000 employees, including over 2,000 medical experts, contribute every day
 to the Group's worldwide success.

 ·      SYNLAB performed around 600 million laboratory tests and achieved
 revenues of €3.25 billion in 2022. Ticker symbol: SYAB; ISIN: DE000A2TSL71

 ·      More information can be found on www.synlab.com
 (http://www.synlab.com)

 Forward looking statements

 This document does not constitute or form a part of, and should not be
 construed as, an offer for sale or subscription of or solicitation of any
 offer to purchase or subscribe for any securities in any jurisdiction.

 Statements made in this document may include forward-looking statements.
 Forward-looking statements include all statements that are not historical
 facts and can be identified by the use of forward-looking terminology such as
 the words "believes", "expects", "expected", "may", "will", "would", "should",
 "seeks", "pro forma", "anticipates", "intends", "plans", "estimates",
 "estimated", or the negative of any thereof or other variations thereof or
 comparable terminology, or by discussions of strategy or intentions. These
 statements are not guarantees of future actions or performance and involve
 risks, uncertainties and assumptions as to future events that may not prove to
 be accurate. Actual actions or results may differ materially from what is
 expressed or forecasted in these forward-looking statements. As a result,
 these statements speak only as of the date they were made and SYNLAB
 undertakes no obligation to publicly update or revise any forward-looking
 statements, whether as a result of new information, future events or
 otherwise. It should be noted that past performance is not a guide to future
 performance. Interim results are not necessarily indicative of full-year
 results.

 End of Media Release

Issuer: SYNLAB AG

Key word(s): Health

 10.10.2023 CET/CEST Dissemination of a Press Release, transmitted by EQS News
 - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
 Financial/Corporate News and Press Releases.
 Archive at www.eqs-news.com

 

About SYNLAB

·      SYNLAB Group is the leader in medical diagnostic services and
specialty testing in Europe. The Group offers a full range of innovative and
reliable medical diagnostics to patients, practising doctors, hospitals and
clinics, governments and corporates.

·      Providing the leading level of service within the industry,
SYNLAB is the partner of choice for routine and specialty diagnostics in human
and veterinary medicine. The Group continuously innovates medical diagnostic
services for the benefit of patients and customers.

·      SYNLAB operates in more than 30 countries across four continents
and holds leading positions in most markets, regularly reinforcing the
strength of its network through a proven acquisition strategy. More than
28,000 employees, including over 2,000 medical experts, contribute every day
to the Group's worldwide success.

·      SYNLAB performed around 600 million laboratory tests and achieved
revenues of €3.25 billion in 2022. Ticker symbol: SYAB; ISIN: DE000A2TSL71

·      More information can be found on www.synlab.com
(http://www.synlab.com)

 

Forward looking statements

This document does not constitute or form a part of, and should not be
construed as, an offer for sale or subscription of or solicitation of any
offer to purchase or subscribe for any securities in any jurisdiction.

Statements made in this document may include forward-looking statements.
Forward-looking statements include all statements that are not historical
facts and can be identified by the use of forward-looking terminology such as
the words "believes", "expects", "expected", "may", "will", "would", "should",
"seeks", "pro forma", "anticipates", "intends", "plans", "estimates",
"estimated", or the negative of any thereof or other variations thereof or
comparable terminology, or by discussions of strategy or intentions. These
statements are not guarantees of future actions or performance and involve
risks, uncertainties and assumptions as to future events that may not prove to
be accurate. Actual actions or results may differ materially from what is
expressed or forecasted in these forward-looking statements. As a result,
these statements speak only as of the date they were made and SYNLAB
undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise. It should be noted that past performance is not a guide to future
performance. Interim results are not necessarily indicative of full-year
results.

 

End of Media Release

Issuer: SYNLAB AG

Key word(s): Health

10.10.2023 CET/CEST Dissemination of a Press Release, transmitted by EQS News
- a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

 Language:  English
 Company:   SYNLAB AG
            Moosacher Straße 88
            80809 Munich
            Germany
 Phone:     +49 1701183753
 E-mail:    ir@synlab.com
 Internet:  www.synlab.com/
 ISIN:      DE000A2TSL71
 WKN:       A2TSL7
 Indices:   SDAX
 Listed:    Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in
            Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAXBLFFXBLLFBV